PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 1758828

Angina clinical trial methodology.

I Ford
View original source ↗Export metadata ↓

Abstract

This paper reviews the general structure of clinical trials with special reference to those in the area of angina. In particular, aspects of experimental design in exercise testing, ambulatory monitoring and mortality studies are examined critically. Parallel group and crossover studies are compared and contrasted. Sensitivity analysis of the power of any proposed trial is recommended, and problems that can arise in the area of event rate estimation are illustrated. Additional problems associated with trials involving combination therapies, trials with no placebo group and regression to the mean are discussed.

Explore related subjects

Angina PectorisClinical Trials as TopicHumansResearch DesignStatistics as TopicJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

I Ford. 1991. Angina clinical trial methodology.. https://pubmed.ncbi.nlm.nih.gov/1758828/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Effect of a hypoglycemic agent on ischemic preconditioning in patients with type 2 diabetes and stable angina pectoris.

OBJECTIVE: Ischemic preconditioning is an increased tolerance to myocardial ischemia during the second of two consecutive exercise tests. ATP-sensitive K(+) channel blockers, such as glinides and sulfonylurea drugs, can induce loss of ischemic preconditioning. This study aimed to investigate the effects of repaglinide, a hypoglycemic agent with an affinity for myocardial ATP-sensitive K (+)channels, on the results of consecutive exercise tests in patients with diabetes and multivessel coronary artery disease. METHODS: Forty-two patients with type 2 diabetes and chronic stable angina pectoris, and two-vessel or three-vessel disease participated in this study. The patients underwent two consecutive treadmill exercise tests (phase 1). On the day after these exercise tests, 2 mg of oral repaglinide was given to the patients. One week later, two exercise tests were repeated consecutively (phase 2). RESULTS: All patients achieved 1.0-mm ST-segment depression during the four exercise tests (T1, T2, T3, and T4). In phase 2, seven patients improved in time to onset of 1.0-mm ST-segment depression. The worsening of the time to onset of 1.0-mm ST-segment depression in phase 2 demonstrated ischemic preconditioning block in 83.3% of patients (P=0.0001). Even the postexercise electrocardiographic parameters (ST-segment depression morphology and magnitude and arrhythmias) were significantly different between the groups with and without pharmacologic ischemic preconditioning block (P=0.031). CONCLUSIONS: Repaglinide, an oral hypoglycemic agent with ATP-sensitive K(+) channel-blocker activity, eliminated the myocardial ischemic preconditioning in patients with coronary disease and diabetes.

Angina Pectoris↗